Elarekibep |
| Catalog No.GC72469 |
Elarekibep (PRS-060) (AZD1402) is a high affinity, slowly dissociating, long-acting full antagonist of IL-4Ra.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2485020-60-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Elarekibep (PRS-060) (0-10 µM) inhibits IL-4- or IL-13-induced STAT-6 phosphorylation with IC50 values of 0.12 nM and 0.10 nM, respectively[1].
PRS-060 (0-10 µM) inhibits hIL-4 or hIL-13 indued proliferation of TF-1 cells with IC50 values of 0.87 nM and 0.92 nM, respectively[1].
PRS-060 (0-10 µM) inhibits hIL-13 induced human epithelial cell mucus transdifferentiation with an IC50 value of 0.3 nM[1].
PRS-060 (i.t; 2, 10, 50 µg) inhibits IL-13-induced eotaxin-1 expression in the lung and ovalbumin-induced acute allergic inflammation in the humanized mouse[1].
References:
[1]. Gabriele Matschiner, et al. Elarekibep (PRS-060/AZD1402): a new class of inhaled Anticalin medicine targeting IL-4Ra for T2 endotype asthma. J Allergy Clin Immunol. 2022 Dec 30;S0091-6749(22)02588-X.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *